Literature DB >> 10488081

Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.

A Zaika1, N Marchenko, U M Moll.   

Abstract

The Mdm2 oncoprotein mediates p53 degradation at cytoplasmic proteasomes and is the principal regulator for maintaining low, often undetectable levels of p53 in unstressed cells. However, a subset of human tumors including neuroblastoma constitutively harbor high levels of wild type p53 protein localized to the cytoplasm. Here we show that the abnormal p53 accumulation in such cells is due to a profound resistance to Mdm2-mediated degradation. Overexpression of Mdm2 in neuroblastoma (NB)(1) cell lines failed to decrease the high steady state levels of endogenous p53. Moreover, exogenous p53, when introduced into these cells, was also resistant to Mdm2-directed degradation. This resistance is not due to a lack of Mdm2 expression in NB cells or a lack of p53-Mdm2 interaction, nor is it due to a deficiency in the ubiquitination state of p53 or proteasome dysfunction. Instead, Mdm2-resistant p53 from NB cells is associated with covalent modification of p53 and masking of the modification-sensitive PAb 421 epitope. This system provides evidence for an important level of regulation of Mdm2-directed p53 destruction in vivo that is linked to p53 modification.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488081     DOI: 10.1074/jbc.274.39.27474

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Hsp70 interactions with the p53 tumour suppressor protein.

Authors:  M Zylicz; F W King; A Wawrzynow
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

Review 2.  Pharmacological activation of wild-type p53 in the therapy of leukemia.

Authors:  Kensuke Kojima; Jo Ishizawa; Michael Andreeff
Journal:  Exp Hematol       Date:  2016-06-18       Impact factor: 3.084

3.  Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells.

Authors:  Jinxiong Wei; Toni A Nagy; Anna Vilgelm; Elena Zaika; Seth R Ogden; Judith Romero-Gallo; Maria B Piazuelo; Pelayo Correa; Mary K Washington; Wael El-Rifai; Richard M Peek; Alexander Zaika
Journal:  Gastroenterology       Date:  2010-06-12       Impact factor: 22.682

4.  Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2.

Authors:  S Sengupta; B Wasylyk
Journal:  Genes Dev       Date:  2001-09-15       Impact factor: 11.361

5.  Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors.

Authors:  Anna E Vilgelm; Mary K Washington; Jinxiong Wei; Heidi Chen; Vladimir S Prassolov; Alexander I Zaika
Journal:  Mol Cancer Ther       Date:  2010-03-02       Impact factor: 6.261

6.  Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells.

Authors:  S Sengupta; J L Vonesch; C Waltzinger; H Zheng; B Wasylyk
Journal:  EMBO J       Date:  2000-11-15       Impact factor: 11.598

7.  Expression of the p53 homologue p63alpha and DeltaNp63alpha in the neoplastic sequence of Barrett's oesophagus: correlation with morphology and p53 protein.

Authors:  P A Hall; A C Woodman; S J Campbell; N A Shepherd
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

8.  A novel function for p53: regulation of growth cone motility through interaction with Rho kinase.

Authors:  Qingyu Qin; Michel Baudry; Guanghong Liao; Albert Noniyev; James Galeano; Xiaoning Bi
Journal:  J Neurosci       Date:  2009-04-22       Impact factor: 6.167

9.  Estrogen receptor-dependent proteasomal degradation of the glucocorticoid receptor is coupled to an increase in mdm2 protein expression.

Authors:  H Karimi Kinyamu; Trevor K Archer
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

10.  Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function.

Authors:  Natalie C Jones; Megan L Lynn; Karin Gaudenz; Daisuke Sakai; Kazushi Aoto; Jean-Phillipe Rey; Earl F Glynn; Lacey Ellington; Chunying Du; Jill Dixon; Michael J Dixon; Paul A Trainor
Journal:  Nat Med       Date:  2008-02-03       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.